 89bio Inc NASDAQ: ETNB announced topline results from the ENTRIGUE Phase 2 proof-of-concept study of pegozafermin for severe hypertriglyceridemia SHTG. Hypertriglyceridemia is characterized by high triglycerides TG levels, a type of fat, in the bloodstream. 